Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Published on by Network Science

Dr. Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Reliance Life Sciences Pvt Ltd | India

Dr. Nikhil Sudhir Sathe (PhD), currently associated with Laboratory Animal Research Services (LARS), is a distinguished researcher with over 20 years of expertise in drug discovery and preclinical evaluation of new chemical entities. His extensive professional experience encompasses in vitro genotoxicology, cell and microbial culture (aerobic, anaerobic, and viral systems including rabies virus), and small laboratory animal studies. Throughout his career at Reliance Life Sciences, Vimta Labs, Dabur Research Centre, and Wockhardt Research Centre, Dr. Sathe has demonstrated exceptional proficiency in GLP-compliant laboratory practices, including bacterial reverse mutation, chromosomal aberration, micronucleus, ELISA, cytotoxicity, and microbial monitoring assays. His early research contributions involved innovative in vitro models for evaluating the efficacy of antimicrobial and cosmetic products. Academically, he holds a Master’s and Bachelor’s degree in Microbiology from Shivaji University, Kolhapur, both with distinction. Dr. Sathe has contributed significantly to scientific literature with publications in reputed journals such as Vaccine, Microbial Pathogenesis, Infectious Medicine, and BioMed, focusing on bacteriophage therapy and vaccine development against multidrug-resistant pathogens and SARS-CoV-2. His scholarly achievements are complemented by active participation in national conferences and workshops, reflecting his deep commitment to advancing microbiological and biomedical research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Unveiling Lytic Bacteriophages as Promising Biotherapeutics for the Control of Multidrug-Resistant Pseudomonas aeruginosa", CS Nikhil Sathe, Eugene Athan, Arnab Kapat, BioMed, 2025.

"Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus", N Sathe, S Shaikh, M Bhavsar, L Parte, A Gadiparthi, S Kad, S Sensarma, Vaccine, 2024.

"Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae-Unraveling efficacy through innovative", N Sathe, C Suphioglu, E Athan, A Kapat, Microbial Pathogenesis, 2024.

"Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment", N Sathe, P Beech, L Croft, C Suphioglu, A Kapat, E Athan, Infectious medicine 2, 2023.

"Development of a novel therapy using bacteriophages: An alternative to antibiotics", NS Sathe, Deakin University, 2023.

Nurulhasanah Othman | Technological Networks | Best Researcher Award

Published on by Network Science

Dr. Nurulhasanah Othman | Technological Networks | Best Researcher Award

University of Science | Malaysia

Dr. Nurulhasanah Othman is a distinguished researcher recognized for her extensive contributions in the fields of molecular parasitology, proteomics, and infectious disease research. As a Principal Investigator and Co-Researcher on numerous national and university-funded projects, her work reflects a deep commitment to advancing biomedical science and public health. She currently leads a national grant project under the Ministry of Education Malaysia (Kementerian Pendidikan Malaysia) focusing on elucidating the potential inhibitory roles of dextromethorphan and azathioprine targeting Rho GTPase to combat metronidazole-resistant E. histolytica HM1-IMSS (MTZR). Her collaborative projects span a range of innovative studies, including comparative proteome profiling in cervical cancer tissues, identification of immunogenic proteins in G. duodenalis, exploration of antibody profiles in Strongyloides stercoralis, and the development of novel multiplex qPCR assays for triple-negative breast cancer markers. Dr. Nurulhasanah has also served as the Principal Investigator for multiple University Sains Malaysia (USM) research grants, including investigations into pyrethroid resistance in Aedes aegypti, proteomic analyses of Entamoeba histolytica for vaccine development, and protein detection studies using MALDI-TOF/TOF technology. As a Co-Researcher, she has contributed to large-scale genome projects, such as the genomic and proteomic analyses of Malaysian mangrove crab species and horseshoe crabs, as well as molecular diagnostic assay development for Leptospira spp. detection. Through her leadership and interdisciplinary collaborations, Dr. Nurulhasanah has made significant strides in proteomic-based pathogen research, genomic studies, and the pursuit of novel molecular tools for disease control and therapeutic innovation.

Profiles: Orcid ID | Scopus

Featured Publications

"Application of Proteomics to the Study of the Therapeutics and Pathogenicity of Giardia duodenalis"

"Entamoeba histolytica: Membrane and Non-Membrane Protein Structure, Function, Immune Response Interaction, and Vaccine Development"

"A Review: Natural and Synthetic Compounds Targeting Entamoeba histolytica and Its Biological Membrane"

"Evaluation of Total Female and Male Aedes aegypti Proteomes Reveals Significant Predictive Protein–Protein Interactions, Functional Ontologies, and Differentially Abundant Proteins"

"Entamoeba histolytica: Proteomics Bioinformatics Reveal Predictive Functions and Protein–Protein Interactions of Differentially Abundant Membrane and Cytosolic Proteins"

June Round | Biological Networks | Best Researcher Award 

Published on by Network Science

Dr. June Round | Biological Networks | Best Researcher Award 

University of Utah | United States

Author Profiles

Scopus

Google Scholar

Early Academic Pursuits

Dr. June Round’s academic journey reflects a foundation of dedication and scholarly excellence. Beginning with a B.S. in Biology (Cum Laude) at California Lutheran University, she distinguished herself early through departmental honors and multiple scholarships. Her passion for molecular biology led to an M.S. from the University of the Pacific, followed by a D.Phil. in Microbiology, Immunology, and Molecular Genetics at UCLA, supported by highly competitive fellowships. Her formative postdoctoral training at the California Institute of Technology under Sarkis K. Mazmanian provided a strong platform to explore the intricate interplay between microbiota and host immunity, setting the stage for her pioneering career.

Professional Endeavors

Currently serving as a Professor at the University of Utah, Dr. Round has held numerous leadership roles including Director of the Mountain West Microbiota Alliance (MoWMA) and Co-Director of the Microbiota and GI Immunology Consortia (MAGIC). She has chaired multiple search committees, overseen postdoctoral studies, and contributed extensively to university-level, college-level, and departmental governance. Her sustained involvement in NIH study sections, national symposia, and scientific advisory boards underscores her standing as a leader in immunology and microbial pathogenesis.

Contributions and Research Focus

Dr. Round’s research focuses on microbiota–immune system interactions, particularly their role in regulating immune tolerance and driving inflammatory diseases. Her laboratory has produced high-impact work elucidating mechanisms by which commensal microbes shape host immunity, contributing to transformative understanding in immunology, microbiology, and gastrointestinal health. Her investigations into toll-like receptors, dysbiosis, and immune regulation have provided new frameworks for therapeutic exploration in autoimmune and inflammatory disorders.

Impact and Influence

The significance of Dr. Round’s research is reflected in her numerous prestigious awards, including the NIH Innovator Award, Packard Fellowship, Pew Scholar Award, Burroughs Wellcome Investigator in Pathogenesis, and the W.M. Keck Research Award. These honors not only recognize her innovative contributions but also demonstrate her influence in shaping the field. She has trained and mentored a generation of young scientists, many of whom now serve as professors, researchers, and clinicians in leading institutions worldwide—an enduring testament to her academic leadership.

Academic Citations and Recognition

Dr. Round’s scholarship has been widely published in top-tier journals including Cell, Nature Reviews Immunology, Science Immunology, and Annual Review of Microbiology. Her reviews and original research articles are highly cited, frequently shaping discourse in immunology and microbiome research. Her contributions extend beyond publications through book chapters and invited conference proceedings, amplifying her thought leadership in the global scientific community.

Legacy and Future Contributions

Dr. Round’s legacy lies in bridging microbiology and immunology, redefining the microbiota’s role in human health and disease. Through her pioneering studies, administrative leadership, and mentorship, she has cultivated a scientific ecosystem that will continue to grow. Moving forward, her leadership in major microbiome initiatives and consortia is poised to advance translational breakthroughs, from novel therapeutics for autoimmune disease to deeper insights into the human–microbe interface.

Conclusion

Dr. June Round’s career reflects the hallmarks of an exceptional researcher: rigorous scholarship, innovative vision, academic leadership, and transformative mentorship. Her pioneering contributions to microbiome and immune system research have reshaped fundamental scientific understanding while fostering future leaders in biomedical science. With her remarkable impact, both in the laboratory and across academic institutions, Dr. Round stands as an exemplary candidate for the Best Researcher Award.

Notable Publications

"Neonatal fungi promote lifelong metabolic health through macrophage-dependent β cell development" 

  • Author: JH Hill, R Bell, L Barrios, H Baird, K Ost, M Greenewood, JK Monts
  • Journal: Science
  • Year: 2025

"The gut microbiome is associated with disease‐free survival in stage I–III colorectal cancer patients" 

  • Author: DA Byrd, V Damerell, MF Gomez Morales, SR Hogue, T Lin, J Ose
  • Journal: International Journal of Cancer
  • Year: 2025

"A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy" 

  • Author: WW Tang, B Battistone, KM Bauer, AM Weis, C Barba, MZH Fadlullah
  • Journal: Cell reports
  • Year: 2025

"Primary tumor microbiomes predict distant metastasis of colorectal cancer" 

  • Author: B Parajuli, V Midya, R Kiddle, N De Jager, S Eggers, D Spakowicz
  • Journal: Cell reports
  • Year: 2025

"Clec12a controls colitis by tempering inflammation and restricting expansion of specific commensals" 

  • Author: TR Chiaro, M Greenewood, KM Bauer, KS Ost, E Stephen-Victor
  • Journal: bioRxiv
  • Year: 2025

Zhengyang Guo | Metabolism Networks | Best Researcher Award

Published on by Network Science

Dr. Zhengyang Guo | Metabolism Networks | Best Researcher Award

Peking University Third Hospital | China

Author Profile 

Scopus

Early Academic Pursuits

Zhengyang Guo’s academic journey began with a strong foundation in the life sciences. He earned his Bachelor’s degree from the School of Basic Medical Sciences at Peking University, which provided him with comprehensive knowledge in biomedical sciences. His pursuit of higher education continued at the Department of Microbiology, Peking University, where he obtained his M.D. degree. This academic background not only reflects his commitment to advancing medical research but also highlights the interdisciplinary foundation that shaped his later contributions in oncology and immunology.

Professional Endeavors

Currently serving as an Assistant Professor at Peking University Third Hospital, Guo has dedicated his professional career to the study of tumor biology and clinical translational research. Alongside his teaching responsibilities, he actively contributes to developing cutting-edge techniques through his involvement in the immunology platform and guiding graduate students in experimental teaching. His professional endeavors balance research, teaching, and technological development, underlining his role as both a researcher and mentor.

Contributions and Research Focus

Dr. Guo’s research primarily centers on tumor epigenetics, tumor metabolism, and the tumor microenvironment. His innovative work investigates molecular mechanisms that influence cancer progression and therapeutic outcomes. Specifically, he has focused on targeting the enzyme SCD1 in combination with EZH2 inhibitors to enhance the efficacy of melanoma treatment and immunotherapy. His projects, supported by prestigious funding bodies such as the National Natural Science Foundation of China and Peking University Medicine Fund, reflect both the clinical relevance and scientific novelty of his work.

Impact and Influence

As an active contributor to the global scientific community, Guo holds membership in the Biophysical Society of China and the Chinese Society of Biochemistry and Molecular Biology. His expertise is recognized internationally, as he serves as a peer reviewer for high-impact journals including Experimental Hematology & Oncology, Cell Communication and Signaling, Apoptosis, and Lipids in Health and Disease. These engagements highlight his influence in shaping scientific dialogue and advancing standards in cancer research.

Academic Cites and Intellectual Property

Guo’s research impact extends beyond publications into intellectual property and patents. He is a co-inventor on multiple patents related to antitumor drug compositions involving EZH2 and SCD1 inhibitors, as well as novel approaches to treating liver cancer using diacylglycerol kinase γ. These patents underscore the translational potential of his work, bridging basic molecular research with therapeutic innovation. His contributions are already shaping new pathways in drug discovery and cancer therapy.

Legacy and Future Contributions

With a strong foundation of academic excellence, innovative research, and translational breakthroughs, Guo is poised to make long-lasting contributions to the field of oncology. His ongoing efforts in epigenetic regulation, tumor metabolism, and immunotherapy strategies hold promise for redefining cancer treatment paradigms. By mentoring future scholars and fostering collaborations across disciplines, he is actively building a legacy that will continue to influence both academia and clinical practice.

Conclusion

In summary, Dr. Zhengyang Guo exemplifies the qualities of a modern medical researcher-a scholar who bridges fundamental biology with clinical application. His journey from early academic pursuits to groundbreaking research in tumor biology reflects dedication, innovation, and leadership. With multiple funded projects, patents, and international recognition, his work significantly impacts the scientific community and promises future advancements in cancer treatment. His career trajectory positions him as a leading figure in biomedical research, with the potential to transform cancer therapy at both national and global levels.

Notable Publications

"3G Internet Diffusion and Secondary Education Attainment: Evidence of Opportunity Cost in Vietnam" 

  • Author: Trang Thi Pham; Bernardo Caldarola
  • Journal: Review of Development Economics
  • Year: 2025